Switch theme
Sign up to access all valuation multiples
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
1981
57
LTM Revenue $4.7M
Last FY EBITDA -$16.2M
$28.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CollPlant has a last 12-month revenue (LTM) of $4.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, CollPlant achieved revenue of $0.5M and an EBITDA of -$16.2M.
CollPlant expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CollPlant valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $3.5M | XXX | -$1.1M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | -216% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$16.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3148% | XXX | XXX | XXX |
| EBIT | -$12.7M | XXX | -$17.3M | XXX | XXX | XXX |
| EBIT Margin | -270% | XXX | -3350% | XXX | XXX | XXX |
| Net Profit | -$12.2M | XXX | -$16.6M | XXX | XXX | XXX |
| Net Margin | -260% | XXX | -3225% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CollPlant's stock price is $3.
CollPlant has current market cap of $36.4M, and EV of $28.5M.
See CollPlant trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.5M | $36.4M | XXX | XXX | XXX | XXX | $-0.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CollPlant has market cap of $36.4M and EV of $28.5M.
CollPlant's trades at 55.4x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate CollPlant's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CollPlant has a P/E ratio of -3.0x.
See valuation multiples for CollPlant and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.4M | XXX | $36.4M | XXX | XXX | XXX |
| EV (current) | $28.5M | XXX | $28.5M | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 55.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCollPlant's last 12 month revenue growth is 191%
CollPlant's revenue per employee in the last FY averaged $9K, while opex per employee averaged $0.3M for the same period.
CollPlant's rule of 40 is 133% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CollPlant's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CollPlant and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 191% | XXX | 491% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3148% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 133% | XXX | -2957% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $9K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2042% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3134% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CollPlant acquired XXX companies to date.
Last acquisition by CollPlant was XXXXXXXX, XXXXX XXXXX XXXXXX . CollPlant acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CollPlant founded? | CollPlant was founded in 1981. |
| Where is CollPlant headquartered? | CollPlant is headquartered in United States of America. |
| How many employees does CollPlant have? | As of today, CollPlant has 57 employees. |
| Who is the CEO of CollPlant? | CollPlant's CEO is Mr. Eran Rotem. |
| Is CollPlant publicy listed? | Yes, CollPlant is a public company listed on NAS. |
| What is the stock symbol of CollPlant? | CollPlant trades under CLGN ticker. |
| When did CollPlant go public? | CollPlant went public in 2021. |
| Who are competitors of CollPlant? | Similar companies to CollPlant include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of CollPlant? | CollPlant's current market cap is $36.4M |
| What is the current revenue of CollPlant? | CollPlant's last 12 months revenue is $4.7M. |
| What is the current revenue growth of CollPlant? | CollPlant revenue growth (NTM/LTM) is 191%. |
| What is the current EV/Revenue multiple of CollPlant? | Current revenue multiple of CollPlant is 6.1x. |
| Is CollPlant profitable? | Yes, CollPlant is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
